Moderate to Severe Alzheimer's Disease
Conditions
Keywords
donepezil, memantine, moderately severe Alzheimer's disease, severe Alzheimer's disease
Brief summary
The trial will examine whether pharmacological treatment with donepezil, memantine or combination of memantine and donepezil is any better than a placebo (dummy) treatment in people with Alzheimer's disease who have reached the moderate to severe stage of illness. Using a double blind design, where neither the investigators nor participants know who is receiving which treatment, participants will be randomly assigned to one of these four treatment groups (donepezil and memantine, memantine only, donepezil only or placebo). In order to keep both the investigators and participants blind to drug allocation a double dummy design will be necessary. This means that each participant will receive 2 treatments - either an active form or placebo of each of the 2 study drugs. Hypotheses are: 1. Patients with Alzheimer's disease (AD) who continue donepezil beyond the point of transition from moderate to severe dementia continue to show significantly less decline on ratings of cognitive function and activities of daily living over the following 12 months than those discontinuing donepezil. 2. Patients with AD who change to memantine therapy in place of donepezil at the point of transition from moderate to severe dementia show significantly smaller decline on ratings of cognitive function and activities of daily living over the following 12 months than those who receive placebo. 3. Patients given the combination of memantine and donepezil at the point of transition from moderate to severe dementia show significant additive or synergistic benefits on measures of activities of daily living and cognitive function after 12 months compared to those patients continuing on either drug as a single treatment.
Detailed description
This trial will involve the withdrawal of drug participants that are currently on (donepezil) and in arm 4, the participant will only be on placebo treatment. It is important to include this arm of the study as a key objective in looking at the benefit of continuing donepezil and therefore a placebo arm should be present as a comparator. To reduce the risk to participants of withdrawing donepezil too early in their illness, an inclusion criteria is that the participant is at a stage in their disease whereby the prescribing clinician feels a change in drug prescription may be appropriate.
Interventions
DRUGMemantine
20mg memantine
DRUGDonepezil
10mg donepezil
DRUGPlacebo donepezil
Placebo donepezil
DRUGPlacebo memantine
Placebo memantine
Sponsors
King's College London
Study design
Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
Participants will be patients who meet NINCDS-ADRDA criteria for probable or possible Alzheimer's disease (McKhann et al, 1984). In addition they will meet all of the following criteria: 1. SMMSE = 5 to 13 (13 chosen as NICE threshold of 10 plus 1 SD on SMMSE score) 2. Continuously prescribed donepezil for at least 3 months 3. Maintained on 10mg donepezil in previous 6 weeks. 4. No changes in prescription of any psychotropic (antipsychotic, antidepressant, benzodiazepine) medication in previous 6 weeks. 5. Prescribing clinician considers (based on NICE guidance, discussions with patient and carer and clinical judgement) that change of drug treatment (i.e. stop donepezil or introduce memantine) may be appropriate. 6. Patient is community resident and has family or professional carer or is visited on at least a daily basis by carer. 7. Patient agrees to participate if considered capable (see section 7.5) 8. Main carer (informal or professional) consents to their own involvement and the patient's involvement -
Exclusion criteria
To maximise the generalisability of the study data, exclusions will be kept to a minimum. These will include: 1. Patient has severe, unstable or poorly controlled medical conditions apparent from physical examination or clinical history. 2. Patient is already prescribed memantine. 3. Patient is unable to take trial medications because of contra-indications or previous adverse or allergic reactions. 4. Patient is involved in another clinical trial. 5. Clinician considers patient would not be compliant with trial medication. -
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cognitive Function measured with the Standardised MMSE (SMMSE). | 4 years |
| Activities of Daily Living measured with the Bristol Activities of Daily Living scale (BADLS). | 4 years |
Secondary
| Measure | Time frame |
|---|---|
| Care-giver burden measured with the General Health Questionnaire. | 4 years |
| Non-cognitive dementia symptoms measured with the Neuropsychiatric Inventory (NPI) and the Cohen-Mansfield Agitation Inventory. | 4 years |
| Institutionalisation defined as permanent transition from living in an independent household to a care home, NHS continuing care unit or hospital and measured with questions taken from the CSRI and telephone interviews. | 4 years |
| Cost effectiveness assessed through consideration of the combination of costs generated from the Client Service Receipt Inventory (CSRI) and the assessments of function and quality of life (BADLS, DEMQOL, EQ-5D). | 4 years |
| Health-related quality of life measured with the EQ-5D (Euroqol Group 1990) and the DEMQOL-Proxy (Smith et al 2004) - a carer-rated and disease-specific measure of quality of life in dementia. | 4 years |
Countries
United Kingdom
Outcome results
None listed